|
1
|
Pavlidis N, Briasoulis E, Hainsworth J and
Greco FA: Diagnostic and therapeutic management of cancer of an
unknown primary. Eur J Cancer. 39:1990–2005. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Matsubara N, Mukai H, Nagai S and Itoh K:
Review of primary unknown cancer: Cases referred to the National
Cancer Center Hospital East. Int J Clin Oncol. 15:578–582. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pouessel D, Thezenas S, Culine S, Becht C,
Senesse P and Ychou M: Hepatic metastases from carcinomas of
unknown primary site. Gastroenterol Clin Biol. 29:1224–1232. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Pavlidis N and Fizazi K: Carcinoma of
unknown primary (CUP). Crit Rev Oncol Hematol. 69:271–278. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kwee TC and Kwee RM: Combined FDG-PET/CT
for the detection of unknown primary tumors: Systematic review and
meta-analysis. Eur Radiol. 19:731–744. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tamam MO, Mulazimoglu M, Guveli TK, Tamam
C, Eker O and Ozpacaci T: Prediction of survival and evaluation of
diagnostic accuracy whole body 18F-fluora-2-deoxyglucose positron
emission tomography/computed tomography in the detection carcinoma
of unknown primary origin. Eur Rev Med Pharmacol Sci. 16:2120–2130.
2012.PubMed/NCBI
|
|
7
|
Hemminki K, Bevier M, Hemminki A and
Sundquist J: Survival in cancer of unknown primary site:
Population-based analysis by site and histology. Ann Oncol.
23:1854–1863. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fehri R, Rifi H, Alboueiri A, Malouche D,
Ayadi M, Rais H and Mezlini A: Carcinoma of unknown primary:
Retrospective study of 437 patients treated at Salah Azaiez
Institute. Tunis Med. 91:205–208. 2013.PubMed/NCBI
|
|
9
|
FernandezCotarelo MJ, GuerraVales JM,
Colina F and de la Cruz J: Prognostic factors in cancer of unknown
primary site. Tumori. 96:111–116. 2010.PubMed/NCBI
|
|
10
|
Kwee TC, Basu S, Cheng G and Alavi A: FDG
PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging.
37:635–644. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abruzzese JL, Abbruzzese MC, Hess KR,
Raber MN, Lenzi R and Frost P: Unknown primary carcinoma: Natural
history and prognostic factors in 657 consecutive patients. J Clin
Oncol. 12:1272–1280. 1994.PubMed/NCBI
|
|
12
|
Briasoulis E, Kalofonos H, Bafaloukos D,
Samantas E, Fountzilas G, Xiros N, Skarlos D, Christodoulou C,
Kosmidis P and Pavlidis N: Carboplatin plus paclitaxel in unknown
primary carcinoma: A phase II Hellenic Cooperative Oncology Group
Study. J Clin Oncol. 18:3101–3107. 2000.PubMed/NCBI
|
|
13
|
Nishimori H, Takahashi S, Kiura K, Ennishi
D, Kobayashi T, Sano K, Shinozaki E, Yokoyama M, Mishima Y, Terui
Y, et al: Cancer of unknown primary site: A review of 28 cases and
the efficacy of cisplatin/docetaxel therapy at a single institute
in Japan. Acta Med Okayama. 64:285–291. 2010.PubMed/NCBI
|
|
14
|
Lee J, Hahn S, Kim DW, Kim J, Kang SN, Rha
SY, Lee KB, Kang JH and Park BJ: Evaluation of survival benefits by
platinums and taxans for an unfavourable subset of carcinoma of
unknown primary: A systematic review and meta-analysis. Br J
Cancer. 108:39–48. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pentheroudakis G, Lazaridis G and Pavlidis
N: Axillary nodal metastases from carcinoma of unknown primary
(CUPAX): A systematic review of published evidence.
Breast Cancer Res Treat. 119:1–11. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Briasoulis E, Pavlidis N and Felip E: ESMO
Guidelines Working Group: Cancers of unknown primary site: ESMO
clinical recommendations for diagnosis, treatment and follow-up.
Ann Oncol. 20 (Suppl 4):154–155. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pasterz R, Savaraj N and Burgess M:
Prognostic factors in metastatic carcinoma of unknown primary. J
Clin Oncol. 4:1652–1657. 1986.PubMed/NCBI
|
|
18
|
Kodaira M, Takahashi S, Yamada S, Ueda K,
Mishima Y, Takeuchi K, Yamamoto N, Ishikawa Y, Yokoyama M, Saotome
T, et al: Bone metastasis and poor performance status are
prognostic factors for survival of carcinoma of unknown primary
site in patients treated with systemic chemotherapy. Ann Oncol.
21:1163–1167. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Petrakis D, Pentheroudakis G, Voulgaris E
and Pavlidis N: Prognostication in cancer of unknown primary (CUP):
Development of a prognostic algorithm in 311 cases andreview of the
literature. Cancer Treat Rev. 39:701–708. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lazaridis G, Pentheroudakis G, Fountzilas
G and Pavlidis N: Liver metastases from cancer of unknown primary
(CUPL): A retrospective analysis of presentation, management and
prognosis in 49 patients and systematic review of the literature.
Cancer Treat Rev. 34:693–700. 2008. View Article : Google Scholar : PubMed/NCBI
|
